Bayer receives first approval worldwide for Lynkuet (elinzanetant) in the UK as treatment of moderate to severe vasomotor symptoms associated with menopause (€27.77, 0.00)
Bayer files for EU approval of gadoquatrane (€27.33, 0.00)
Bayer AG announces US Supreme Court asks for views of Solicitor General in Durnell case following petition (€26.60, -0.38)
BridgeBio raises $300M through partial capped monetization of BEYONTTRA European royalty ($44.86, 0.00)
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London (SEK 26.94, 0.00)
StreetAccount Summary - Trading higher/lower: EU mid-morning
European Commission grants label extension in EU for Eylea 8 mg with extended treatment intervals of up to 6 months for treatment of two major retinal diseases (€26.28, 0.00)
EMA CHMP publishes summary of opinions for June 2025 meeting
EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for Bayer's Nubeqa (€27.10, +0.16)
EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances for medicinal product Imreplys
Powered by FactSet Research Systems Inc.